ClinicalTrials.gg
TerminatedNCT05573555Updated Oct 27, 2026

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

A Phase 1/2 interventional study of ARV-471 and Ribociclib in Breast Cancer, sponsored by Pfizer. Terminated at 31 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph 2 and DDI components were not initiated.
Updated Oct 27, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.

Enrollment
9th of 12
20 · median 48
Started
2023
with 5 others
Phase 1/2
5 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 9th largest by enrollment, is one of 6 that started in 2023, is one of 5 in phase 1/2, and was the 7th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vepdegestrant

vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing vepdegestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.

This study is seeking participants who have breast cancer that:

  • is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy
  • is sensitive to hormonal therapy (it is called estrogen receptor positive); and
  • is no longer responding to previous treatments

This study is divided into separate sub-studies.

For Sub-Study B:

All participants will receive ARV-471 and a medicine called ribociclib. ARV-471 and ribociclib will be given at the same time by mouth, at home, 1 time a day.

The experiences of people receiving the study medicine will be examined. This will help determine if the study medicine is safe and effective.

Participants will continue to take ARV-471 and ribociclib until their cancer is no longer responding, or side effects become too severe. They will have visits at the study clinic about every 4 weeks.

Read the detailed description

C4891023 is a prospective, open-label, multicenter, Phase 1b/2 sub-study to evaluate the safety, antitumor activity, and PK of ARV-471 with ribociclib in the treatment of participants with A/MBC. The sub-study is part of Umbrella platform, TACTIVE-U, comprising multiple sub-studies that independently evaluate ARV-471 in participants with with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Advanced or Metastatic Breast Cancer. ARV-471 will act as the backbone therapy given in combination with other anticancer agents thought to have clinical relevance in ER+ breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • TACTIVE-U; Umbrella study; PROTAC; metastatic breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • histological or cytological diagnosis of ER+ and - advanced/ breast cancer that is not amendable to surgical resection with curative intent (≥1% ER+ stained cells on the most recent tumor ).
  • prior anticancer therapies: at least 1 and no more than 2 for advanced/metastatic disease; 1, and only 1, line of any CDK4/6 inhibitor-based regimen is required (in any setting eg adjuvant, metastatic)
  • at least 1 as defined by v1.1.
  • PS ≤1.

Exclusion criteria

Exclusion Criteria:

  • visceral crisis at risk of life-threatening complications in the short term
  • known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions.
  • newly diagnosed , or symptomatic CNS metastases, carcinomatous meningitis, or . Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and for at least 14 days prior to enrollment in the of study.
  • history of any other tumor within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix.
  • inflammatory breast cancer
  • impaired cardiovascular function or cardiovascular diseases
  • concurrent administration of medications, food, or herb supplements that are strong inhibitors and strong/moderate inducers of and drugs known to predispose to Torsade de Pointes or prolongation.
  • renal impairment, not adequate liver function and/or bone marrow function
  • known active infection
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    ARV-471 in combination with Ribociclib

    ARV-471 administered orally QD continuously and Ribociclib administered orally QD consecutively for 21 days followed by 7 days off treatment on 28-day cycles

    Drug: ARV-471 · Drug: Ribociclib

Interventions

  • Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

  • Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Dose Limiting Toxicities

    Dose Limiting Toxicities rate for ARV-471 in combination with Ribociclib, estimated based on data from DLT-evaluable participants during the DLT observation period (Cycle 1 \[28 days\]).

    Time frame: Cycle 1 (28 days)

  2. Phase 2: Percentage of Participants With Objective Response by investigator assessment

    Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

    Time frame: Up to approximately 1 year

  3. Drug Drug Interaction cohort: Area Under the Curve from Time Zero to end of dosing interval Evaluation of ribociclib with and without co-administration of ARV-471

    Exposure (AUCtau) of ribociclib with and without co-administration of ARV-471

    Time frame: pre-dose Day -1, 1, 8, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 8, 29 and 43

  4. Drug Drug Interaction cohort: Maximum Plasma Concentration (Cmax) of ribociclib with and without co-administration of ARV-471

    Concentration (Cmax) of ribociclib with and without co-administration of ARV-471

    Time frame: pre-dose Day -1, 1, 8, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 8, 29 and 43

Secondary outcomes

  1. Phase 1b, Drug Drug Interaction cohort and Phase 2: number of participants experiencing any AE, SAE, Treatment Related SAE

    An adverse event (AE) were any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE is any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events. Treatment-related AE is any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were graded by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0) and coded using MedDRA were reported. Grade 1=mild; Grade 2=moderate; Grade 3=severe and Grade 4=life-threatening or disabling and grade 5=death.

    Time frame: Up to 28 days after last dose of study treatment

  2. Phase 1b, Drug Drug Interaction cohort and Phase 2: number of participants with lab abnormalities - chemistry parameters

    Blood samples were collected for analysis of clinical chemistry parameters. These included: alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, \[international unit per liter (IU/L)\] ; Lipase and amilase \[IU/L\] (limited to cycle1 only); Albumin, bilirubin, urea ,calcium, creatinine, glucose, magnesium, phosphate, uric acid chloride, potassium and sodium \[millimol per liter (mmol/L)\]; eGFR \[milliliter per minute (ml/min)\]. Number of participants with chemistry abnormalities by grade as per CTCAE version 5.0 were reported. Grade 1=mild; Grade 2=moderate; Grade 3=severe and Grade 4=life-threatening or disabling and grade 5=death. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, abnormal, or not done.

    Time frame: Up to 28 days after last dose of study treatment

  3. Phase 1b, Drug Drug Interaction cohort and Phase 2: number of participants with lab abnormalities - Hematology and coagulation parameters

    Blood samples were collected for the analysis of following hematology and coagulation parameters: hemoglobin \[g/L\], platelets, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils \[10\^9/L\]; partial thromboplastin time prolonged, international normalized ratio increased, prothrombin time. Number of participants with hematological and coagulation abnormalities by grade as per CTCAE version 5.0 were reported. Grade 1=mild; Grade 2=moderate; Grade 3=severe and Grade 4=life-threatening or disabling and grade 5=death. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, abnormal, or not done.

    Time frame: Up to 28 days after last dose of study treatment

  4. Drug Drug Interaction cohort: number of participants with changes from baseline for ECG parameters

    The following ECG parameters were analyzed and changes from baseline were assessed: heart rate, PR interval, QT interval, QRS interval and QT interval corrected using Fridericia's formula (QTcF).

    Time frame: Up to 28 days after last dose of study treatment

  5. Phase 1b: Percentage of Participants With Objective Response by investigator assessment

    Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. as determined by investigator assessment.

    Time frame: Up to approximately 1 year

  6. Phase 1b and Phase 2: Duration of Response by investigator assessment.

    Duration of Response (DoR) is defined for participants with confirmed OR (CR or PR) as the time from the first documentation of OR to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

    Time frame: Up to approximately 1 year

  7. Phase 1b and Phase2: Percentage of participants with Clinical Benefit Response by investigator assessment.

    Clinical Benefit Response (CBR) is defined as the proportion of participants with Best Overall Response of confirmed CR or PR at any time, or Stable Disease (SD) ≥24 weeks

    Time frame: Up to approximately 1 year

  8. Phase 1b and Phase 2: Progression Free Survival by investigator assessment.

    Progression Free Survival (PFS) is defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 1 year

  9. Phase 1b: Maximum Observed Plasma Concentration (Cmax) of ARV-471 with and without co-administration of ribociclib

    Concentration (Cmax) of ARV-471 with and without co-administration of ribociclib

    Time frame: Phase 1b: pre-dose Day -1, 1, 8, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 8, 29 and 43

  10. Phase 1b Area Under the Curve from Time Zero to end of dosing interval Evaluation of ARV-471 with and without co-administration of ribociclib

    Exposure (AUCtau) of ARV-471 with and without co-administration of ribociclib

    Time frame: Phase 1b: pre-dose Day -1, 1, 8, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 8, 29 and 43

  11. Phase 1b and Phase 2: Maximum Observed Plasma Concentration (Cmax) of ARV-471

    Plasma concentration of ARV-471

    Time frame: Phase 1b: pre-dose Day 8, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 8, 29 and 43 Phase 2: pre and post dose Day 8, 15, 29 and 43; pre - dose Day 57, 113 and 169

  12. Phase 1b and Phase 2: Maximum Observed Plasma Concentration (Cmax) of ARV-473

    Plasma concentration of ARV-473

    Time frame: Phase 1b: pre-dose Day -1, 1, 8, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 8, 29 and 43 Phase 2: pre and post dose Day 8, 15, 29 and 43; pre - dose Day 57, 113 and 169

  13. Phase 1b and Phase 2: Phase 1b: Maximum Observed Plasma Concentration (Cmax) of ribociclib

    Plasma concentration of ribociclib

    Time frame: Phase 1b: pre-dose Day -1, 1, 8, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day 15; post dose Day 8, 29 and 43 Phase 2: pre and post dose Day 8, 15, 29 and 43; pre - dose Day 57, 113 and 169

  14. Phase 2: Overall Survival

    Overall Survival (OS) is defined as the time from the date of first dose of study interventions to the date of death due to any cause

    Time frame: Through study completion, up to approximately 3 year

  15. Phase 2:ctDNA plasma quantitative changes from pre-treatment

    To assess changes from baseline levels in plasma ctDNA with treatment and to evaluate potential predictability of their associations with clinical outcomes.

    Time frame: At predefined intervals throughout the treatment period, up to cycle 3 (each cycle is 28 days) and end of treatment

07

Study locations

31 sites
  • Clinical and Translational Research Unit (CTRU)
    Palo Alto, California 94304, United States
  • Stanford Cancer Institute - Clinical Trials Office
    Palo Alto, California 94304, United States
  • Stanford Women's Cancer Center
    Palo Alto, California 94304, United States
  • UCSF Medical Center at Mission Bay
    San Francisco, California 94158, United States
  • Moffitt Cancer Center - International Plaza
    Tampa, Florida 33607, United States
  • Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center
    Tampa, Florida 33612, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Moffitt McKinley Hospital
    Tampa, Florida 33612, United States
  • Siteman Cancer Center - WUPI
    Shiloh, Illinois 62269, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute - Chestnut Hill
    Newton, Massachusetts 02459, United States
  • Siteman Cancer Center - St Peters
    City of Saint Peters, Missouri 63376, United States
  • Siteman Cancer Center - West County
    Creve Coeur, Missouri 63141, United States
  • Siteman Cancer Center - North County
    Florissant, Missouri 63031, United States
  • Siteman Cancer Center
    St Louis, Missouri 63108, United States
  • Barnes Jewish Hospital Department of Laboratories
    St Louis, Missouri 63110, United States
  • Barnes-Jewish Hospital
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine - Siteman Cancer Center
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Barnes Jewish Hospital Lab- South County
    St Louis, Missouri 63129, United States
  • Siteman Cancer Center - South County
    St Louis, Missouri 63129, United States
  • BC Cancer Vancouver
    Vancouver, British Columbia V5Z 1H7, Canada
  • BC Cancer Vancouver
    Vancouver, British Columbia V5Z 4E6, Canada
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
  • CIUSSS- saguenay-Lac-Saint-Jean
    Chicoutimi, Quebec G7H 5H6, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, Lombardy 20900, Italy
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid, Comunidad de 28041, Spain
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2023 to primary completion in Oct 2026, 43 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2022
First posted
Oct 10, 2022
StartActual
Mar 1, 2023
Primary completionActual
Oct 6, 2026was Dec 2026
CompletionActual
Oct 6, 2026was Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph 2 and DDI components were not initiated.
changed Oct 27, 2026
Sites
2 sites added
Show 2 added (2 United States)
  • Clinical and Translational Research Unit (CTRU) · Palo Alto, United States
  • Stanford Cancer Institute - Clinical Trials Office · Palo Alto, United States
Oct 27, 2026
Primary completion
Dec 30, 2026→Oct 6, 2026 (actual)
Oct 27, 2026
Study completion
Dec 30, 2026→Oct 6, 2026 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Active, not recruiting→Terminated
    Why stopped Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph 2 and DDI components were not initiated.
    2 sites added
    Show 2 added (2 United States)
    • Clinical and Translational Research Unit (CTRU) · Palo Alto, United States
    • Stanford Cancer Institute - Clinical Trials Office · Palo Alto, United States
    Primary completion Dec 30, 2026→Oct 6, 2026 (now actual)
    Study completion Dec 30, 2026→Oct 6, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05573555
Lead sponsor
Pfizer
Collaborators
Arvinas Estrogen Receptor, Inc.
Responsible party
Sponsor
First posted
Oct 10, 2022
Start date
Mar 1, 2023
Primary completion
Oct 6, 2026
Completion
Oct 6, 2026
Last update
Oct 27, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepdegestrant

Start the discussion